Metsera (NASDAQ:MTSR) Stock Price Up 10.6% – What’s Next?

Metsera Inc. (NASDAQ:MTSR)’s share price shot up 10.6% on Thursday . The company traded as high as $79.07 and last traded at $78.92. 1,625,337 shares changed hands during mid-day trading, an increase of 10% from the average session volume of 1,478,660 shares. The stock had previously closed at $71.38.

Analyst Ratings Changes

Several equities research analysts recently issued reports on MTSR shares. Wall Street Zen upgraded Metsera from a “sell” rating to a “hold” rating in a report on Wednesday, October 1st. Leerink Partners restated a “market perform” rating and issued a $57.00 target price (down from $77.00) on shares of Metsera in a research note on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d)” rating on shares of Metsera in a research note on Wednesday, October 8th. Wells Fargo & Company downgraded shares of Metsera from an “overweight” rating to an “equal weight” rating and set a $54.00 price target for the company. in a report on Tuesday, September 30th. Finally, Leerink Partnrs cut shares of Metsera from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 24th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $55.75.

Metsera Stock Up 2.0%

The firm’s fifty day moving average price is $49.99 and its 200-day moving average price is $37.31. The stock has a market cap of $8.76 billion and a P/E ratio of -15.97.

Hedge Funds Weigh In On Metsera

A number of hedge funds have recently modified their holdings of MTSR. Osaic Holdings Inc. boosted its holdings in shares of Metsera by 45.5% during the second quarter. Osaic Holdings Inc. now owns 946 shares of the company’s stock worth $27,000 after purchasing an additional 296 shares during the period. Penserra Capital Management LLC bought a new position in Metsera during the 3rd quarter valued at approximately $50,000. BNP Paribas Financial Markets lifted its holdings in Metsera by 100.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company’s stock worth $46,000 after buying an additional 800 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Metsera by 408.3% in the 3rd quarter. SBI Securities Co. Ltd. now owns 1,601 shares of the company’s stock worth $84,000 after buying an additional 1,286 shares during the last quarter. Finally, Amalgamated Bank grew its position in shares of Metsera by 225.2% in the 3rd quarter. Amalgamated Bank now owns 1,730 shares of the company’s stock worth $91,000 after buying an additional 1,198 shares during the last quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.